The German Association of Gynecological Oncology included the breast cancer diagnostic in its annual update for cancer clinicians.
The recommendations were developed by a working group of the AMP Clinical Practice Committee that included representatives from ACMG, ASCO, and CAP.
The Clinical Pharmacogenetics Implementation Consortium hopes that the terms will be widely adopted by labs and help advance adoption of PGx test results across systems.
However, the task force stopped short of recommending the use of Cologuard or other molecular assays over a variety of well-established non-molecular testing methods.
The recommendations resulted from two meetings that brought together physicians, lab workers, researchers, genetic counselors, and patient families from the US and Canada.
Despite the development of guidelines, researchers still don't always report the age and sex of the lab mice used in their studies.
The network said MDxHealth's ConfirmMDx should be used to screen men at higher risk for prostate cancer despite a negative biopsy.
The new rule is aimed at women with early-stage invasive breast cancer and known hormone and HER2 receptor status.
The three organizations are inviting comment from health professionals on the recommendations.
Researchers are hoping the 100,000-patient WISDOM study will lead to genetically informed breast cancer screening based on a woman's unique risk factors.
A New Zealand minister says the country's genetic modification laws need to be re-examined to help combat climate change, the New Zealand Herald reports.
A new analysis finds some cancers receive more nonprofit dollars than others.
An Australian mother's conviction in the deaths of her children may be re-examined after finding that two of the children carried a cardiac arrhythmia-linked gene variant.
In Science this week: comparative analysis of sex differences in mammal gene expression, and more.